MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Gencor Industries Company Profile (NASDAQ:GENC)

Consensus Ratings for Gencor Industries (NASDAQ:GENC) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Gencor Industries (NASDAQ:GENC)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings History for Gencor Industries (NASDAQ:GENC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/9/2016        
12/9/2014$0.06($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014$0.14$0.17ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/7/2014Q1 14$0.05ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/13/2013Q4$0.24ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2013Q1 2013($0.10)$6.90 million$4.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Gencor Industries (NASDAQ:GENC)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Gencor Industries (NASDAQ:GENC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Gencor Industries (NASDAQ:GENC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/7/2016Marc G ElliottPresidentSell15,000$14.91$223,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2016Marc G ElliottPresidentSell2,000$14.74$29,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Marc G ElliottPresidentSell24,000$14.86$356,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016David AirDirectorSell5,000$13.40$67,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2016Sherry HoutkinMajor ShareholderSell10,000$13.38$133,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Sherry HoutkinMajor ShareholderSell20,000$13.54$270,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2016Sherry HoutkinMajor ShareholderSell50,000$13.11$655,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Marc G. ElliottPresidentSell9,140$12.68$115,895.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Marc G. ElliottPresidentSell19,044$12.74$242,620.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Sherry HoutkinMajor ShareholderSell80,000$9.26$740,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2015Sherry HoutkinMajor ShareholderSell70,000$9.20$644,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Sherry HoutkinMajor ShareholderSell2,948$9.72$28,654.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014Sherry HoutkinMajor ShareholderSell5,000$9.93$49,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Sherry HoutkinMajor ShareholderSell200,000$9.25$1,850,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Sherry HoutkinMajor ShareholderSell5,000$10.18$50,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Sherry HoutkinMajor ShareholderSell5,346$10.23$54,689.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Sherry HoutkinMajor ShareholderSell344$10.20$3,508.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2014Sherry HoutkinMajor ShareholderSell4,984$10.18$50,737.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Sherry HoutkinMajor ShareholderSell2,200$10.16$22,352.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2014Sherry HoutkinMajor ShareholderSell1,208$10.20$12,321.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2014Jeanne M LyonsInsiderSell1,500$10.93$16,395.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2014Jeanne M LyonsInsiderSell2,000$10.97$21,940.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Eric E MellenCFOSell11,051$11.07$122,334.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2013Sherry HoutkinMajor ShareholderSell80,086$8.80$704,756.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Gencor Industries (NASDAQ:GENC)
DateHeadline
06/23/16 09:29 AMGenmab Provides Update on Marketing Authorization Application for Arzerra® (ofatumumab) as Maintenance Therapy for Patients with Relapsed CLL - [at noodls] - PDF Company Announcement Committee for Medicinal Products for Human Use (CHMP) issues negative opinion for Arzerra for maintenance treatment of patients with relapsed CLL Copenhagen, Denmark; June 23, ...
06/09/16 11:59 AMGrant of Warrants to Genmab Employees - [at noodls] - PDF Company Announcement Copenhagen, Denmark; June 9, 2016 -Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to issue 16,800 warrants to employees of the company ...
06/08/16 08:45 AMGencor Industries, Inc. :GENC-US: Earnings Analysis: Q2, 2016 By the Numbers : June 8, 2016 -
05/31/16 10:12 AMGenmab's Total Number of Voting Rights and Total Share Capital - [at noodls] - PDF Copenhagen, Denmark; May 31, 2016 -Genmab A/S (Nasdaq Copenhagen: GEN) announces that pursuant to section 10 of Executive Order no. 1258 of November 9, 2015 on Issuers' Disclosure Obligations, the ...
05/31/16 02:22 AMGenmab to Present at the Goldman Sachs 37th Annual Global Healthcare Conference - [at noodls] - Media Release Copenhagen, Denmark; May 31, 2016 - Genmab A/S (OMX: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the Goldman Sachs 37 Annual Global Healthcare ...
05/30/16 10:10 AMGenmab Achieves USD 30 Million Milestone in DARZALEX® (daratumumab) Collaboration with Janssen - [at noodls] - PDF Company Announcement Genmab to receive USD 30 million milestone payment from Janssen Milestone triggered by first commercial sale of DARZALEX in Europe Copenhagen, Denmark; May 30, 2016 -Genmab A/S ...
05/30/16 10:10 AMGenmab Achieves USD 30 Million Milestone in DARZALEX® (daratumumab) Collaboration with Janssen - [at noodls] - PDF Company Announcement Genmab to receive USD 30 million milestone payment from Janssen Milestone triggered by first commercial sale of DARZALEX in Europe Copenhagen, Denmark; May 30, 2016 -Genmab A/S ...
05/23/16 05:56 AMGenmab Announces European Conditional Marketing Authorization for DARZALEX® (daratumumab) for Multiple Myeloma - [at noodls] - PDF Company Announcement DARZALEX (daratumumab) receives European conditional marketing authorization for heavily pre-treated or double refractory multiple myeloma First CD38 monoclonal antibody approved ...
05/20/16 02:33 AMFirst Participants Dosed in Clinical Study with DuoBody® Product - [at noodls] - Media Release · Treatment of first study participants with DuoBody product marks clinical progress in collaboration with Janssen Copenhagen, Denmark; May 20, 2016 - Genmab A/S (Nasdaq Copenhagen: GEN) ...
05/19/16 06:22 AMDaratumumab and Ofatumumab Data to Be Presented at 21st Congress of EHA - [at noodls] - Media Release ? Daratumumab interim data from Phase III POLLUX study to be presented at EHA ? Daratumumab Phase III CASTOR data to be presented ? Two additional daratumumab abstracts to be presented ? ...
05/18/16 01:32 PMGenmab Announces Positive Topline Result in Phase III POLLUX Study of Daratumumab in Relapsed or Refractory Multiple Myeloma - [at noodls] - Company Announcement Phase III POLLUX study of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma met the primary endpoint at a pre-planned ...
05/18/16 11:02 AMCapital Increase in Genmab as a Result of Employee Warrant Exercise - [at noodls] - Microsoft Word - 23_Warrant Exercise_180516_uk.docx Company Announcement Copenhagen, Denmark; May 18, 2016 - Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 156,348 shares as a consequence ...
05/17/16 03:12 PMOfatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL accepted for priority review by FDA - [at noodls] - PDF Company Announcement US FDA grants Priority Review to sBLA for ofatumumab in combination with fludarabine and cyclophosphamide in relapsed CLL PDUFA target action date of September 10, 2016 Copenhagen, ...
05/10/16 10:18 AMGenmab Announces Financial Results for the First Quarter of 2016 - [at noodls] - PDF May 10, 2016; Copenhagen, Denmark; Interim Report for the First Quarter of 2016 Net Sales of DARZALEX (daratumumab) by Janssen for the first quarter of 2016 were USD 101.9 million, resulting in royalty ...
05/09/16 06:36 PMGencor posts 2Q profit -
05/09/16 03:30 PMGencor Releases Second Quarter Fiscal 2016 Results - [GlobeNewswire] - ORLANDO, Fla., May 09, 2016-- Gencor Industries, Inc. announced today net revenue for the quarter ended March 31, 2016 increased 60.5% to $22.1 million from $13.8 million for the quarter ended March 31, ...
04/22/16 09:59 AMGencor Industries Incorporated (NASDAQ:GENC) Sellers Covered 29.52% of Their Shorts - The stock is up 2.56% or $0.37 after the news, hitting $14.84 per share. About 16,171 shares traded hands. Gencor Industries, Inc. (DE) (NASDAQ:GENC) has risen 59.89% since September 15, 2015 and is uptrending. It has outperformed by 53.61% the S&P500.
04/20/16 09:51 AMGenmab Announces Daratumumab Data to be Presented at 2016 ASCO Annual Meeting - [at noodls] - PDF Company Announcement Oral plenary session presentation on daratumumab Phase III Castor study data Trial in progress poster presentation from Phase I study of subcutaneous daratumumab Copenhagen, Denmark; ...
04/20/16 12:12 AMGenmab Updates Financial Guidance for 2016 - [at noodls] - PDF Company Announcement Genmab improves financial guidance for 2016 Improvement driven by DARZALEX sales Rapid uptake of the product since launch Copenhagen, Denmark; April 20, 2016 -Genmab A/S (Nasdaq ...
04/15/16 01:06 PMGencor Industries Inc. (GENC) - Gencor Industries, Inc., together with its subsidiaries, designs, manufactures, and sells heavy machinery used in the production of highway construction materials, synthetic fuels, and environmental control equipment. The company offers hot-mix asphalt ...
04/08/16 04:35 PMETF’s with exposure to Gencor Industries, Inc. : April 8, 2016 -
04/07/16 09:13 AMGencor Industries, Inc. :GENC-US: Earnings Analysis: Q1, 2016 By the Numbers -
04/04/16 01:05 PMPatent Infringement Lawsuit Filed Against Genmab and Janssen in the United States Regarding DARZALEX® - [at noodls] - PDF Company Announcement Morphosys AG files patent infringement complaint against Genmab and Janssen Biotech, Inc. with the US District Court of Delaware Complaint is under US patent no. 8,263,746 Copenhagen, ...
04/01/16 10:41 AMCHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Relapsed and Refractory Multiple Myeloma - [at noodls] - PDF Company Announcement CHMP issued positive opinion for DARZALEX for relapsed and refractory multiple myeloma Final decision from European Commission expected in the coming months Copenhagen, Denmark; ...
03/30/16 11:21 AMGenmab Announces Positive Interim Result in Phase III Castor Study of Daratumumab in Relapsed or Refractory Multiple Myeloma - [at noodls] - PDF Company Announcement Phase III Castor study of daratumumab in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma met primary endpoint at pre-planned interim analysis ...
03/10/16 04:01 PMGENCOR INDUSTRIES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
03/05/16 01:39 PMInsider Trading Alert - GENC, LPLA And RMD Traded By Insiders - Shares are up 18.58% year-to-date as of the close of trading on Wednesday. Gencor Industries, Inc., together with its subsidiaries, designs, manufactures, and sells heavy machinery used in the production of highway construction materials, synthetic fuels ...
02/27/16 01:49 PMGencor Industries, Inc. Company Profile - Gencor Industries is a US manufacturer of heavy machinery used in the production of highway construction materials, synthetic fuels, and environmental control equipment. Subsidiary Bituma designs and manufactures hot-mix asphalt batch plants used in the ...
02/10/16 09:15 AMGencor posts 1Q profit -
02/10/16 08:56 AMGencor Releases First Quarter Fiscal 2016 Results - [GlobeNewswire] - ORLANDO, Fla., Feb. 10, 2016-- Gencor Industries, Inc. announced today net revenues increased 111% to $13.3 million for the quarter ended December 31, 2015 compared to $6.3 million for the quarter ended ...
02/10/16 07:54 AMGENCOR INDUSTRIES INC Files SEC form 10-Q, Quarterly Report -
01/19/16 02:25 PMGenmab Announces U.S. FDA Approval of Arzerra® (ofatumumab) as Extended Treatment for Recurrent or Progressive CLL - [at noodls] - PDF Company Announcement Arzerra now approved by U.S. FDA for use for extended treatment of patients with recurrent or progressive CLL Approval based on data from interim analysis of Phase III PROLONG ...
01/07/16 01:38 AMDaratumumab Data Published in The Lancet Shows Encouraging Efficacy in Heavily Pretreated and Refractory Multiple Myeloma - [at noodls] - PDF Media Release The Lancet published data from the Phase II study of daratumumab as a monotherapy to treat heavily pretreated and refractory multiple myeloma Updated data was presented at the American ...
12/21/15 05:53 AMGenmab Announces Completion of Agreement to Transfer Remaining Ofatumumab Rights - [at noodls] - PDF Media Release Agreement to transfer remaining ofatumumab rights from GSK to Novartis now effective Copenhagen, Denmark; December 21, 2015 - Genmab A/S (Nasdaq Copenhagen: GEN) announced today that ...
12/18/15 07:42 AMArticles of Association for Genmab A/S - [at noodls] - Articles of Association for Genmab A/S
12/15/15 09:43 AMGenmab to Present at the 34th Annual J.P. Morgan Healthcare Conference - [at noodls] - PDF Media Release Copenhagen, Denmark; December 15, 2015 - Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 34 Annual J.P. ...
12/12/15 12:04 PMGENCOR INDUSTRIES INC Financials -
12/10/15 12:29 PMReport Pursuant to Section 28a of the Danish Securities Trading Act - [at noodls] - PDF Company Announcement Copenhagen, Denmark; December 10, 2015 - In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Genmab A/S (Nasdaq ...
12/10/15 12:19 PMGrant of Restricted Stock Units to Board Members and Management and Grant of Warrants to Management and Employees in Genmab - [at noodls] - PDF Company Announcement Copenhagen, Denmark; December 10, 2015 - Genmab A/S ( Nasdaq Copenhagen : GEN) announced today that at a board meeting the board decided to grant 23,145 restricted stock units ...
12/09/15 06:48 PMGENCOR RELEASES FOURTH QUARTER AND FISCAL YEAR 2015 RESULTS - [at noodls] - FOR IMMEDIATE RELEASE: December 8, 2015 (PRIME NEWSWIRE) - Gencor Industries, Inc., (NASDAQ:GENC) announced today net revenue for the quarter ended September 30, 2015 increased 69.4% to $8.3 million compared ...
12/09/15 03:26 PMGencor Industries, Inc.: Leading performance but fundamentals not looking strong? -
12/09/15 08:09 AMGENCOR INDUSTRIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh -
12/09/15 08:09 AMGENCOR INDUSTRIES INC Files SEC form 10-K, Annual Report -
12/08/15 01:15 PMGencor reports 4Q loss -
About Gencor Industries

Gencor Industries, Inc. is a manufacturer of heavy machinery used in the production of highway construction materials, synthetic fuels, and environmental control equipment. The Company designs, manufactures, and sells machinery and related equipment used for the production of asphalt and highway construction materials. The Company's products include asphalt plants, combustion systems and fluid heat transfer systems. The Company's products are manufactured in approximately two facilities in the United States. The Company manufactures and produces hot-mix asphalt plants used in the production of asphalt paving materials. The Company manufactures related asphalt plant equipment, including hot mix storage silos, fabric filtration systems, cold feed bins and other plant components. The Company also manufactures Combustion Systems and Industrial Incinerators, and Fluid Heat Transfer Systems.

Industry, Sector and Symbol:
  • Sector: Industrial Products
  • Industry: Farm & Construction Machinery
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GENC
  • CUSIP:
Key Metrics:
  • Previous Close: $15.53
  • 50 Day Moving Average: $14.70
  • 200 Day Moving Average: $13.56
  • P/E Ratio: 115.90
  • P/E Growth: 0.00
  • Market Cap: $148.40M
  • Current Quarter EPS Consensus Estimate: $0.34 EPS
Additional Links:
Gencor Industries (NASDAQ:GENC) Chart for Saturday, July, 2, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha